The Role of Pharmacology in Pediatric Oncology: Developments in Oncology, cartea 44
Editat de D.G. Poplack, Luisa Massimo, P. Cornaglia-Ferrarisen Limba Engleză Paperback – 2 oct 2011
Din seria Developments in Oncology
- 5% Preț: 360.70 lei
- 5% Preț: 384.80 lei
- 5% Preț: 345.71 lei
- 5% Preț: 1096.98 lei
- 5% Preț: 360.86 lei
- 5% Preț: 1125.88 lei
- 5% Preț: 3183.63 lei
- 5% Preț: 371.30 lei
- 5% Preț: 374.57 lei
- 5% Preț: 1417.91 lei
- 5% Preț: 375.34 lei
- 5% Preț: 368.57 lei
- 5% Preț: 1102.10 lei
- 5% Preț: 368.37 lei
- 15% Preț: 604.56 lei
- 5% Preț: 1425.76 lei
- 5% Preț: 1119.10 lei
- 5% Preț: 374.57 lei
- 5% Preț: 1416.09 lei
- 5% Preț: 723.21 lei
- 5% Preț: 713.33 lei
- 5% Preț: 1424.16 lei
- 5% Preț: 718.65 lei
- 5% Preț: 367.64 lei
- 5% Preț: 1423.22 lei
- 5% Preț: 1097.71 lei
- 5% Preț: 3836.15 lei
- 5% Preț: 1100.64 lei
- 5% Preț: 1109.08 lei
- 5% Preț: 1419.39 lei
- 5% Preț: 1439.31 lei
- 5% Preț: 1114.71 lei
Preț: 371.10 lei
Preț vechi: 390.63 lei
-5% Nou
Puncte Express: 557
Preț estimativ în valută:
71.02€ • 73.27$ • 60.11£
71.02€ • 73.27$ • 60.11£
Carte tipărită la comandă
Livrare economică 04-18 martie
Preluare comenzi: 021 569.72.76
Specificații
ISBN-13: 9789401083959
ISBN-10: 9401083959
Pagini: 340
Ilustrații: 336 p.
Dimensiuni: 155 x 235 x 18 mm
Greutate: 0.48 kg
Ediția:1987
Editura: SPRINGER NETHERLANDS
Colecția Springer
Seria Developments in Oncology
Locul publicării:Dordrecht, Netherlands
ISBN-10: 9401083959
Pagini: 340
Ilustrații: 336 p.
Dimensiuni: 155 x 235 x 18 mm
Greutate: 0.48 kg
Ediția:1987
Editura: SPRINGER NETHERLANDS
Colecția Springer
Seria Developments in Oncology
Locul publicării:Dordrecht, Netherlands
Public țintă
ResearchCuprins
Principles of Antineoplastic Therapy in Children.- 1. Clinical pharmacokinetics for the pediatric oncologist.- 2. The pharmacology of antineoplastic agents in children.- 3. Clinical pharmacology of anticancer drugs in children: differences and similarities between children and adults.- Pharmacologic reasons for treatment failure.- 4. Drug resistance in medical and pediatric oncology.- 5. Genetic reasons for pharmacologic treatment failure: gene amplification.- 6. New approaches to overcome drug resistance.- Methods of drug delivery.- 7. New methods of administering old drugs: iv infusion of mercaptopurine.- 8. Regional therapy: an overview.- 9. Pharmacologic approaches to the treatment of central nervous system malignancy.- Use of new agents in children.- 10. Phase I and II trials in pediatric cancer patients: a rationale.- 11. Guidelines for conduct of Phase I studies in children.- Pharmacology of antileukemic agents.- 12. Factors affecting the clinical pharmacology of antileukemic drugs.- 13. Potentiation of 6-mercaptopurine after time and dose-dependent pretreatment with methotrexate in malignant human T- and B-lymphoblasts.- 14. The effect of methotrexate on purine and pyrimidine deoxyribonucleoside triphosphate pools and on cell viability and cell-phase distribution in malignant human T- and B-lymphoblasts.- 15. 7-Hydroxy-methotrexate production after methotrexate therapy.- Late effects of chemotherapy.- 16. An overview of adverse late effects of cancer chemotherapy in children.- 17. Focusing on late effects in long-term survivors of childhood leukemia and lymphomas.- High dose chemotherapy.- 18. Purging procedures: a critical step in autologous bone marrow transplantation.- 19. ‘High dose’ cisplatinum: a phase II study.- Biological response modifiers.- 20.Induction of differentiation: a possible therapeutic approach to the treatment of hematologic malignancy.- 21. The development of 9-substituted purines as immunomodulators.- 22. Immunopharmacologic profile of an L-Arginine hypoxanthine dervative: PCF/01.- 23. Antineoplastic drugs modulating c-myc expression in K562, induce erythroid differentiation and modify, with IFN, susceptibility to NK cell mediated lysis.- 24. In vivo treatment with recombinant interleukin-2 (IL-2) stimulates the differentiation of natural killer (NK) precursor cells.- 25. Immunopharmacology studies related to in vitro infection with HTLV-I.